Increasing evidence indicates that CD19 CAR T cell therapy also enables a profound depletion of B cells in patients with SLE and patients suffering from other types of B cell–mediated autoimmune disease, an approach that was able to facilitate a sustained and drug-free remission in such patients (13–16). This evidence concerns the gene CD19 and systemic lupus erythematosus.